WO2008021729A3 - Compositions et procédés pour traiter, réduire, améliorer ou soulager des maladies ophtalmiques du segment postérieur - Google Patents

Compositions et procédés pour traiter, réduire, améliorer ou soulager des maladies ophtalmiques du segment postérieur Download PDF

Info

Publication number
WO2008021729A3
WO2008021729A3 PCT/US2007/074943 US2007074943W WO2008021729A3 WO 2008021729 A3 WO2008021729 A3 WO 2008021729A3 US 2007074943 W US2007074943 W US 2007074943W WO 2008021729 A3 WO2008021729 A3 WO 2008021729A3
Authority
WO
WIPO (PCT)
Prior art keywords
ameliorating
compositions
treating
reducing
methods
Prior art date
Application number
PCT/US2007/074943
Other languages
English (en)
Other versions
WO2008021729A2 (fr
Inventor
Raili Kerppola
Gary Phillips
Zhenze Hu
Keith Wayne Ward
Original Assignee
Bausch & Lomb
Raili Kerppola
Gary Phillips
Zhenze Hu
Keith Wayne Ward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2660167A priority Critical patent/CA2660167C/fr
Priority to EP07813637A priority patent/EP2051710B1/fr
Priority to BRPI0714817-8A priority patent/BRPI0714817A2/pt
Priority to AU2007284176A priority patent/AU2007284176B2/en
Priority to PL07813637T priority patent/PL2051710T3/pl
Priority to JP2009523901A priority patent/JP2010500364A/ja
Priority to MX2009001333A priority patent/MX2009001333A/es
Priority to DK07813637.1T priority patent/DK2051710T3/da
Application filed by Bausch & Lomb, Raili Kerppola, Gary Phillips, Zhenze Hu, Keith Wayne Ward filed Critical Bausch & Lomb
Priority to AT07813637T priority patent/ATE531366T1/de
Priority to SI200730833T priority patent/SI2051710T1/sl
Priority to ES07813637T priority patent/ES2373999T3/es
Publication of WO2008021729A2 publication Critical patent/WO2008021729A2/fr
Publication of WO2008021729A3 publication Critical patent/WO2008021729A3/fr
Priority to HK09106710.7A priority patent/HK1127556A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition pour traiter, réduire, améliorer ou soulager un état ou un trouble du fond de l'œil causant une inflammation, laquelle composition comprend un agoniste du récepteur des glucocorticoïdes dissocié (« DIGRA »). Les compositions peuvent également inclure d'autres agents anti-inflammatoires, des agents anti-angiogéniques ou des combinaisons de ceux-ci. La composition peut être formulée pour une application topique, une injection ou une implantation. La composition peut être administrée seule ou en combinaison avec une autre procédure choisie pour améliorer les résultats du traitement.
PCT/US2007/074943 2006-08-07 2007-08-01 Compositions et procédés pour traiter, réduire, améliorer ou soulager des maladies ophtalmiques du segment postérieur WO2008021729A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2009001333A MX2009001333A (es) 2006-08-07 2007-08-01 Composiciones y metodos para tratar, reducir, mejorar o aliviar enfermedades oftalmicas del segmento posterior.
BRPI0714817-8A BRPI0714817A2 (pt) 2006-08-07 2007-08-01 composiÇço, mÉtodo para tratar, reduzir, melhorar ou aliviar um condiÇço ou distérbio da parte posterior dos olhos, uso de um digra, e, mÉtodo para fabricar uma composiÇço
AU2007284176A AU2007284176B2 (en) 2006-08-07 2007-08-01 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
PL07813637T PL2051710T3 (pl) 2006-08-07 2007-08-01 Kompozycje i sposoby leczenia, zmniejszania, polepszania lub łagodzenia chorób tylnego odcinka oka
JP2009523901A JP2010500364A (ja) 2006-08-07 2007-08-01 後部眼科疾患を治療、または軽減、または改善、または緩和するための組成物と方法
CA2660167A CA2660167C (fr) 2006-08-07 2007-08-01 Compositions et procedes pour traiter, reduire, ameliorer ou soulager des maladies ophtalmiques du segment posterieur
DK07813637.1T DK2051710T3 (da) 2006-08-07 2007-08-01 Sammensætninger og fremgangsmåder til behandling, reducering, forbedring eller lindring af sygdomme i det bageste øjensegment
EP07813637A EP2051710B1 (fr) 2006-08-07 2007-08-01 Compositions et procédés pour traiter, réduire, améliorer ou soulager des maladies ophtalmiques du segment postérieur
AT07813637T ATE531366T1 (de) 2006-08-07 2007-08-01 Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments
SI200730833T SI2051710T1 (sl) 2006-08-07 2007-08-01 Sestavki in postopki za zdravljenje, zmanjšanje, izboljšanje ali lajšanje oftalmičnih bolezni posteriornega segmenta
ES07813637T ES2373999T3 (es) 2006-08-07 2007-08-01 Composiciones y métodos para tratar, reducir, mejorar o aliviar enfermedades oftálmicas de segmento posterior.
HK09106710.7A HK1127556A1 (en) 2006-08-07 2009-07-22 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83607806P 2006-08-07 2006-08-07
US60/836,078 2006-08-07

Publications (2)

Publication Number Publication Date
WO2008021729A2 WO2008021729A2 (fr) 2008-02-21
WO2008021729A3 true WO2008021729A3 (fr) 2008-10-09

Family

ID=38823645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/074943 WO2008021729A2 (fr) 2006-08-07 2007-08-01 Compositions et procédés pour traiter, réduire, améliorer ou soulager des maladies ophtalmiques du segment postérieur

Country Status (19)

Country Link
US (1) US20080031884A1 (fr)
EP (1) EP2051710B1 (fr)
JP (1) JP2010500364A (fr)
KR (1) KR20090051076A (fr)
CN (1) CN101522187A (fr)
AT (1) ATE531366T1 (fr)
AU (1) AU2007284176B2 (fr)
BR (1) BRPI0714817A2 (fr)
CA (1) CA2660167C (fr)
CY (1) CY1112269T1 (fr)
DK (1) DK2051710T3 (fr)
ES (1) ES2373999T3 (fr)
HK (1) HK1127556A1 (fr)
MX (1) MX2009001333A (fr)
PL (1) PL2051710T3 (fr)
PT (1) PT2051710E (fr)
SI (1) SI2051710T1 (fr)
TW (1) TWI378928B (fr)
WO (1) WO2008021729A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2056799B1 (fr) * 2006-08-31 2013-07-31 Bausch & Lomb Incorporated Compositions et méthodes de traitement ou de prévention du glaucome ou de son évolution
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
KR20100067684A (ko) * 2007-11-05 2010-06-21 보오슈 앤드 롬 인코포레이팃드 약물 전달을 위한 비히클로서의 수불혼화성 물질
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
RU2559585C2 (ru) * 2013-12-26 2015-08-10 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ диагностики раннего воздействия вредных производственных факторов на организм работников, занятых в производстве синтетических смол не более 5 лет
WO2020152193A1 (fr) 2019-01-22 2020-07-30 Akribes Biomedical Gmbh Modificateurs sélectifs du récepteur de glucocorticoïdes pour le traitement de la mauvaise cicatrisation de plaies cutanées

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316465B1 (en) * 1998-06-27 2001-11-13 Photogenesis, Inc. Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists
WO2004005229A1 (fr) * 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
WO2004110385A2 (fr) * 2003-06-11 2004-12-23 Bristol-Myers Squibb Company Modulateurs du recepteur des glucocorticoides et procede associe
WO2006050998A1 (fr) * 2004-11-12 2006-05-18 Bayer Schering Pharma Aktiengesellschaft Derives de quinoline et d'isoquinoline 5-substitues, procede permettant de les produire et leur utilisation comme antiphlogistique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4580559A (en) * 1984-07-24 1986-04-08 Esperance Francis A L Indirect ophthalmoscopic photocoagulation delivery system for retinal surgery
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316465B1 (en) * 1998-06-27 2001-11-13 Photogenesis, Inc. Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
WO2004005229A1 (fr) * 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
WO2004110385A2 (fr) * 2003-06-11 2004-12-23 Bristol-Myers Squibb Company Modulateurs du recepteur des glucocorticoides et procede associe
WO2006050998A1 (fr) * 2004-11-12 2006-05-18 Bayer Schering Pharma Aktiengesellschaft Derives de quinoline et d'isoquinoline 5-substitues, procede permettant de les produire et leur utilisation comme antiphlogistique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAMPOL L M ET AL: "Treatment of juxtafoveal and extrafoveal choroidal neovascularization in the era of photodynamic therapy with verteporfin", AMERICAN JOURNAL OF OPHTHALMOLOGY 2002 US, vol. 134, no. 1, 2002, pages 99 - 101, XP002483910, ISSN: 0002-9394 *
MICHEL SHAWKAT SHAFIK ET AL: "Multifocal choroiditis and panuveitis: immunomodulatory therapy.", OPHTHALMOLOGY FEB 2002, vol. 109, no. 2, February 2002 (2002-02-01), pages 378 - 383, XP002483909, ISSN: 0161-6420 *
TENNANT M T ET AL: "Photodynamic Therapy (PDT) in Multifocal Choroiditis (MFC).", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2002, 2002, & ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; FORT LAUDERDALE, FLORIDA, USA; MAY 05-10, 2002, pages Abstract No. 595, XP008092817 *

Also Published As

Publication number Publication date
US20080031884A1 (en) 2008-02-07
EP2051710B1 (fr) 2011-11-02
SI2051710T1 (sl) 2012-02-29
CA2660167A1 (fr) 2008-02-21
HK1127556A1 (en) 2009-10-02
PL2051710T3 (pl) 2012-03-30
PT2051710E (pt) 2012-02-08
EP2051710A2 (fr) 2009-04-29
BRPI0714817A2 (pt) 2013-05-21
ES2373999T3 (es) 2012-02-10
AU2007284176B2 (en) 2013-03-28
JP2010500364A (ja) 2010-01-07
KR20090051076A (ko) 2009-05-20
AU2007284176A1 (en) 2008-02-21
CY1112269T1 (el) 2015-12-09
ATE531366T1 (de) 2011-11-15
WO2008021729A2 (fr) 2008-02-21
TWI378928B (en) 2012-12-11
CN101522187A (zh) 2009-09-02
MX2009001333A (es) 2009-02-13
DK2051710T3 (da) 2012-02-20
TW200815416A (en) 2008-04-01
CA2660167C (fr) 2012-04-10

Similar Documents

Publication Publication Date Title
HK1127556A1 (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
WO2003068171A3 (fr) Procede et composition pour le traitement d'une inflammation et de troubles neurologiques associes au sida
PL363218A1 (en) Compositions for delivery of a cortisol antagonist
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
WO2007143607A3 (fr) Procédé de traitement de la vaginite atrophique
WO2008089307A3 (fr) Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
MX2009009624A (es) Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia.
WO2005074913A3 (fr) Compositions et procedes pour le traitement de la contracture
NZ610068A (en) Compositions comprising povidone-iodine
WO2006002096A3 (fr) Faibles doses de l-citrulline pour traiter des maladies
WO2005115432A3 (fr) Traitement de maladies et de troubles oculaires utilisant des compositions lantibiotiques
WO2009129147A3 (fr) Compositions analgésiques et anti-inflammatoires et méthodes permettant de soulager, de prévenir ou de traiter la douleur et l'inflammation
WO2005074536A3 (fr) Compositions et methodes faisant appel a des inhibiteurs de pompe a protons
WO2005123192A3 (fr) Procede ameliorant le traitement medical de la douleur
WO2008005686A8 (fr) Compositions pharmaceutiques et procédé de traitement de la sécheresse oculaire
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2008112773A3 (fr) Droxidopa et composition pharmaceutique de celle-ci pour le traitement de l'hypotension véhiculée par voie neurale
MX2009002228A (es) Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo.
WO2008012796A3 (fr) Compositions pharmaceutiques comprenant ccl2 et leur utilisation dans le traitement d'une inflammation
WO2006012536A3 (fr) Procedes et compositions pour le traitement de l'intolerance au lactose
HK1141249A1 (en) Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation
PL2061444T3 (pl) Kompozycje i sposoby leczenia, traktowania, kontrolowania, redukowania, łagodzenia lub zapobiegania alergii
WO2007109079A3 (fr) Composition destinee au traitement des douleurs articulaires ou musculaires
MX2013014518A (es) Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio.
TW200738247A (en) Method and composition for treating allergic diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780036646.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07813637

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2660167

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007284176

Country of ref document: AU

Ref document number: MX/A/2009/001333

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009523901

Country of ref document: JP

Ref document number: 903/DELNP/2009

Country of ref document: IN

Ref document number: 2007813637

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007284176

Country of ref document: AU

Date of ref document: 20070801

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097004766

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0714817

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090206